Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.61 |
| ▸ | CLK1 | P49759 | 2/20 | 0.61 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.61 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.61 |
| ▸ | CLK2 | P49760 | 1/20 | 0.61 |
| ▸ | CLK3 | P49761 | 1/20 | 0.61 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.61 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.61 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.61 |
| ▸ | TRPA1 | O75762 | 7/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.52 |
| ▸ | PIM1 | P11309 | 4/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.52 |
| ▸ | QPCT | Q16769 | 1/20 | 0.51 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | PAK4 | O96013 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1142046 | 0.98 | GSK3B (0.59) | GSK3BCLK1CDK5DYRK1ADYRK3 | |
| SCHEMBL1141435 | 0.88 | FGFR1 (0.61) | GSK3BCLK1CDK5DYRK1ADYRK3 | |
| SCHEMBL29732812 | 0.87 | GSK3B (0.65) | GSK3BCLK1CDK5DYRK1ADYRK3 | |
| SCHEMBL11911439 | 0.87 | GSK3B (0.65) | GSK3BCLK1CDK5DYRK1ADYRK3 | |
| Hydrochloric Acid SCHEMBL1141329 | 0.86 | FGFR1 (0.59) | GSK3BCLK1CDK5DYRK1ADYRK3 | |
| SCHEMBL1141318 | 0.84 | ROCK2 (0.53) | GSK3BCLK1CDK5DYRK1ADYRK3 | |
| SCHEMBL19922226 | 0.84 | CLK1 (0.68) | GSK3BCLK1CDK5DYRK1ADYRK3 | |
| Hydrochloric Acid SCHEMBL1141660 | 0.83 | ROCK2 (0.52) | GSK3BCLK1CDK5DYRK1ADYRK3 | |
| SCHEMBL1142257 | 0.82 | TRPA1 (0.49) | GSK3BCLK1CDK5DYRK1ADYRK3 | |
| Hydrochloric Acid SCHEMBL1142090 | 0.81 | TRPA1 (0.48) | GSK3BCLK1CDK5DYRK1ADYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2628482-A1 | Rho kinase inhiitors for use in the treatment of neuroblastoma | Academisch Medisch Centrum (NL) | 2013-08-21 | — | — | EP | claimed |
| US-8232308-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2012-07-31 | — | — | US | claimed |
| EP-2468729-A1 | Novel indazole derivative | UBE INDUSTRIES, LTD. (JP) | 2012-06-27 | — | — | EP | claimed |
| US-20110039891-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2011-02-17 | — | — | US | claimed |
| US-7855222-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2010-12-21 | — | — | US | claimed |
| US-20100216778-A1 | PAIN REMEDY CONTAINING ROCK INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2010-08-26 | — | — | US | claimed |
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2009-10-22 | — | — | US | claimed |
| US-7563906-B2 | Indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2009-07-21 | — | — | US | claimed |
| US-20090029970-A1 | PAIN REMEDY CONTAINING ROCK INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-01-29 | — | — | US | claimed |
| EP-1854484-A1 | PAIN REMEDY CONTAINING ROCK INHIBITOR | Astellas Pharma Inc. (JP) | 2007-11-14 | — | — | EP | claimed |
| US-20070129404-A1 | Novel indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2007-06-07 | — | — | US | claimed |
| EP-1679308-A1 | NOVEL INDAZOLE DERIVATIVE | Ube Industries, Ltd. (JP) | 2006-07-12 | — | — | EP | claimed |
| US-20180110837-A1 | METHODS AND ASSAYS RELATING TO MACROPHAGE DIFFERENTIATION | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-04-26 | — | — | US | disclosed |
| EP-2961405-A1 | METHODS AND ASSAYS RELATING TO MACROPHAGE DIFFERENTIATION | The Brigham and Women's Hospital, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20150297679-A1 | METHODS AND ASSAYS RELATING TO MACROPHAGE DIFFERENTIATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | disclosed |
| WO-2014093773-A1 | METHODS AND ASSAYS RELATING TO MACROPHAGE DIFFERENTIATION | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20070129404-A1 | Novel indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129404-A1 | Novel indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129404-A1 | Novel indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| EP-1679308-A1 | NOVEL INDAZOLE DERIVATIVE | Ube Industries, Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297679-A1 | METHODS AND ASSAYS RELATING TO MACROPHAGE DIFFERENTIATION | MYADM, CD14, CD68 | GSK3B 4381/4885CLK1 1495/4885CDK5 4835/4885 |
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, RHOT2 | GSK3B 1406/4885CLK1 1203/4885CDK5 569/4885 |
| US-20180110837-A1 | METHODS AND ASSAYS RELATING TO MACROPHAGE DIFFERENTIATION | MYADM, CD14, CD68 | GSK3B 4381/4885CLK1 1495/4885CDK5 4835/4885 |
| US-20070129404-A1 | Novel indazole derivatives | CIT, ROCK1, ROCK2 | GSK3B 512/4885CLK1 2967/4885CDK5 49/4885 |
| US-20110039891-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, ROCK2 | GSK3B 1341/4885CLK1 1196/4885CDK5 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.